Press release

11/20/2020

Nanobiotix files registration statement for proposed initial public offering in the United States

Download en

11/17/2020

Nanobiotix announces two new phase II trials evaluating NBTXR3 in combination with anti-PD-1 for the treatment of head and neck cancer

Download en

11/12/2020

Nanobiotix announces positive new pre-clinical data suggesting radioenhancer NBTXR3 could have a significant impact in immunotherapy

Download en

11/10/2020

Nanobiotix announces positive first clinical data showing conversion of anti-PD-1 non-responders to responders with radioenhancer NBTXR3

Download en

10/26/2020

Nanobiotix provides update on global clinical development plan for first-in-class radioenhancer NBTXR3

Download en

10/23/2020

Nanobiotix announces third quarter 2020 revenue

Download en

10/20/2020

Nanobiotix announces four presentations at the Society for Immunotherapy of Cancer (SITC) 35th anniversary annual meeting

Download en

10/13/2020

Nanobiotix announces first patient injected with NBTXR3 in pancreatic cancer and safe to proceed notifications for two additional trials from U.S. FDA

Download en

09/04/2020

Nanobiotix announces half-year financial statements as at June 30, 2020

Download en

08/03/2020

Update to the Nanobiotix press release dated july 28, 2020

Download en

Update to the Nanobiotix press release dated july 28, 2020

The following pages contain information regarding the [potential] capital increase of Nanobiotix. For regulatory reasons, the distribution of the content of such information is restricted. Consequently, please fill out the fields below to access such information.

Your country:

Access to this information is restricted to persons who are located outside the United States, Canada, Japan and Australia.

The following pages include information pertaining to a potential capital increase of Nanobiotix, which would be conducted pursuant to a public offering in France exclusively, if it is conducted in the future at all.

This website and the information contained herein are not intended for, and may not be accessed by, or distributed or disseminated to, persons resident or physically present in the United States of America (including its territories, the “United States”), Canada, Japan or Australia, and do not constitute an offer to sell or the solicitation of an offer to purchase or acquire, any shares or other securities of Nanobiotix in the United States, Canada, Japan or Australia.  The shares of Nanobiotix referred to on this website have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), and may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act.

All persons residing outside of France and outside of the United States, Canada, Japan and Australia who wish to access the documents contained on this website should first ensure that they are not subject to local laws or regulations that prohibit or restrict their right to access this website, or require registration or approval for any acquisition of securities by them.  No such registration or approval has been or will be obtained outside of France. Nanobiotix assumes no responsibility if there is a violation of applicable law and regulations by any person.

I certify that:

I am a resident of and physically present in France;

Or

(2) I am a resident of and physically present in a Member State of the European Economic Area (other than France) or the United Kingdom which is subject to the provisions of Regulation (EU) 2017/1129 of the European Parliament of the Council of June 14, 2017 (the “Prospectus Regulation”), and I am a qualified investor as defined in the Prospectus Regulation, 

And

(3) I am not a resident of or physically present in the United States, Canada, Japan or Australia.

I have read and understood the foregoing, and hereby make the certifications above and agree to comply with all of the above restrictions:

Sorry

Not for access within the United States, Canada, Japan or Australia

07/28/2020

Nanobiotix successfully raises approximatively €20 million in placement of ordinary new shares with US and european investors

Download en

Nanobiotix successfully raises approximatively €20 million in placement of ordinary new shares with US and european investors

The following pages contain information regarding the [potential] capital increase of Nanobiotix. For regulatory reasons, the distribution of the content of such information is restricted. Consequently, please fill out the fields below to access such information.

Your country:

Access to this information is restricted to persons who are located outside the United States, Canada, Japan and Australia.

The following pages include information pertaining to a potential capital increase of Nanobiotix, which would be conducted pursuant to a public offering in France exclusively, if it is conducted in the future at all.

This website and the information contained herein are not intended for, and may not be accessed by, or distributed or disseminated to, persons resident or physically present in the United States of America (including its territories, the “United States”), Canada, Japan or Australia, and do not constitute an offer to sell or the solicitation of an offer to purchase or acquire, any shares or other securities of Nanobiotix in the United States, Canada, Japan or Australia.  The shares of Nanobiotix referred to on this website have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), and may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act.

All persons residing outside of France and outside of the United States, Canada, Japan and Australia who wish to access the documents contained on this website should first ensure that they are not subject to local laws or regulations that prohibit or restrict their right to access this website, or require registration or approval for any acquisition of securities by them.  No such registration or approval has been or will be obtained outside of France. Nanobiotix assumes no responsibility if there is a violation of applicable law and regulations by any person.

I certify that:

I am a resident of and physically present in France;

Or

(2) I am a resident of and physically present in a Member State of the European Economic Area (other than France) or the United Kingdom which is subject to the provisions of Regulation (EU) 2017/1129 of the European Parliament of the Council of June 14, 2017 (the “Prospectus Regulation”), and I am a qualified investor as defined in the Prospectus Regulation, 

And

(3) I am not a resident of or physically present in the United States, Canada, Japan or Australia.

I have read and understood the foregoing, and hereby make the certifications above and agree to comply with all of the above restrictions:

Sorry

Not for access within the United States, Canada, Japan or Australia

07/27/2020

Nanobiotix launches a placement

Download en

Title

The following pages contain information regarding the [potential] capital increase of Nanobiotix. For regulatory reasons, the distribution of the content of such information is restricted. Consequently, please fill out the fields below to access such information.

Your country:

Access to this information is restricted to persons who are located outside the United States, Canada, Japan and Australia.

The following pages include information pertaining to a potential capital increase of Nanobiotix, which would be conducted pursuant to a public offering in France exclusively, if it is conducted in the future at all.

This website and the information contained herein are not intended for, and may not be accessed by, or distributed or disseminated to, persons resident or physically present in the United States of America (including its territories, the “United States”), Canada, Japan or Australia, and do not constitute an offer to sell or the solicitation of an offer to purchase or acquire, any shares or other securities of Nanobiotix in the United States, Canada, Japan or Australia.  The shares of Nanobiotix referred to on this website have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), and may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act.

All persons residing outside of France and outside of the United States, Canada, Japan and Australia who wish to access the documents contained on this website should first ensure that they are not subject to local laws or regulations that prohibit or restrict their right to access this website, or require registration or approval for any acquisition of securities by them.  No such registration or approval has been or will be obtained outside of France. Nanobiotix assumes no responsibility if there is a violation of applicable law and regulations by any person.

I certify that:

I am a resident of and physically present in France;

Or

(2) I am a resident of and physically present in a Member State of the European Economic Area (other than France) or the United Kingdom which is subject to the provisions of Regulation (EU) 2017/1129 of the European Parliament of the Council of June 14, 2017 (the “Prospectus Regulation”), and I am a qualified investor as defined in the Prospectus Regulation, 

And

(3) I am not a resident of or physically present in the United States, Canada, Japan or Australia.

I have read and understood the foregoing, and hereby make the certifications above and agree to comply with all of the above restrictions:”

Sorry

Not for access within the United States, Canada, Japan or Australia

07/17/2020

Nanobiotix announces revenue for second quarter 2020 and first half year 2020

Download en

06/17/2020

Nanobiotix receives feedback from US FDA to advance phase III head and neck cancer study design and CMC development plan for NDA

Download en

06/10/2020

Nanobiotix spinoff Curadigm validates novel nanoprimer technology in RNA therapeutics

Download en

06/08/2020

Nanobiotix secures €10M in non-dilutive financing

05/29/2020

Nanobiotix announces positive first results from phase I expansion in locally advanced head and neck cancer at ASCO 2020

Download en

05/14/2020

Publication of the 2019 Universal Registration Document

Download en

05/06/2020

Nanobiotix announces first phase I trial with NBTXR3 in pancreatic cancer is safe to proceed per US FDA

Download en

04/30/2020

Nanobiotix announces first quarter 2020 revenues

Download en

04/21/2020

Nanobiotix provides updates on clinical development continuity in the context of the Covid-19 crisis

Download en

03/17/2020

Nanobiotix 2019 Annual results

Download en

02/28/2020

Nanobiotix 2019 Q4 and annual revenues

Download en

02/10/2020

Scientific Clinical | Nanobiotix announces Fast Track designation granted by U.S. FDA for investigation of first-in-class NBTXR3 in Head and Neck cancer

Download en

01/07/2020

Scientific Clinical | Nanobiotix announces plan for global phase III Head and Neck cancer registration trial along with overall development update

Download en

12/16/2019

Corporate | Nanobiotix receives the 2019 Prix Galien award for first-in-class Hensify

Download en

11/12/2019

Scientific Clinical | Nanobiotix announces new results from pre-clinical immuno-oncology study at SITC 2019

Download en

10/25/2019

Financial | Nanobiotix announces third quarter 2019 revenue

Download en

09/18/2019

Scientific Clinical | Phase I study results show first-in-class NBTXR3 could present as a valuable option for patients with hepatocellular carcinoma or liver metastasis

Download en

09/11/2019

Financial | Nanobiotix announces half year financial statements of june 30, 2019

Download en

09/11/2019

Financial | Nanobiotix announces second quarter 2019 revenue

Download en

09/11/2019

Scientific Clinical | Nanobiotix announces publication of phase III soft tissue sarcoma data for first-in-class NBTXR3 in the Lancet Oncology

Download en

09/11/2019

Corporate | Nanobiotix announces new organizational structure as the company enters its next stage after first european market approval

Download en

08/08/2019

Nanobiotix launches a placement

Download en

06/04/2019

Corporate | Nanobiotix appoints new chief medical officer as the company evolves after achievement of european market approval

Download en

05/28/2019

Scientific Clinical | Nanobiotix announces the launch of Curadigm : A new nanotechnology platform for healthcare

Download en

04/30/2019

Financial | Nanobiotix announces first quarter 2019 revenue

Download en

04/25/2019

Financial | Laurent Levy, CEO, increases stake in Nanobiotix's capital

Download en

04/09/2019

Nanobiotix raises approximately EUR 29.5 million in placement of ordinary new shares

Download en

Nanobiotix raises approximately EUR 29.5 million in placement of ordinary new shares

The following pages contain information regarding the placement of Nanobiotix. For regulatory reasons, the distribution of the content of such information is restricted. Consequently, please fill out the fields below to access such information.

Your country:

Access to this information is restricted to persons who are located outside the United States, Canada, Japan and Australia.

This information is not intended for, and shall not be
accessible, published, distributed or circulated to persons resident or located in the United States of America (the “United States”, which shall include its territories and possessions), Canada, Japan or Australia, and is not an offer to subscribe for or sell, nor a solicitation of an offer to subscribe for or buy shares of Nanobiotix in the United States, Canada, Japan or Australia.
With respect to Member States of the European Economic Area that have transposed European Directive 2003/71/EC of the European Parliament and European Council (as amended in particular by Directive 2010/73/EU to the extent that the said Directive has been transposed into each Member State of the European Economic Area) (the “Prospectus Directive”), no action has been taken or will be taken topermit a public offering of the securities of 
 Nanobiotix which would require the publication of a prospectus in any Member State. Shares in Nanobiotix may not be offered or sold in the United States unless registered with the Securities and Exchange Commission under the U.S. Securities Act of 1933, as amended, or unless an exemption from such registration applies. Nanobiotix does not intend to register securities or conduct a public offering in the United States, or in
any other jurisdiction. Access to the information and documents contained in the following pages may be illegal in certain countries and only certain categories of persons may be authorized to access this information and these documents. Any person resident in a country other than France, the United States, Canada, Japan or Australia who wishes to
access the information and documents contained on this website must first satisfy himself that he is not subject to local laws or regulations prohibiting or restricting such right of access or requiring registration or approval of the securities in order to acquire them. Nanobiotix will not accept any liability arising out of the breach by any person of the applicable laws or regulations.
I therefore certify that:
(1) I am not a resident of the United States, Canada, Australia or Japan nor am I currently physically present in any one of those countries;
(2) I am authorized to access the information and documents presented on thiswebsite without being subject to any legal restriction and without any further actionbeing necessary on the part of Nanobiotix.
I have read and understood the above declarations and certify below that they areaccurate, and hereby undertake to comply with all the conditions set forth on thispage.

Sorry

Access to this information is restricted to persons who are located outside the United States, Canada, Japan and Australia.

04/09/2019

Nanobiotix raises approximately EUR 29.5 million in placement of ordinary new shares

Download en

04/04/2019

Scientific Clinical | Nanobiotix announces first ever radioenhancer to receive european market approval

Download en

04/02/2019

Scientific Clinical | Combination of first-in-class NBTXR3, radiotherapy, and anti-PD-1 immunotherapy demonstrate efficacy in treating resistant pre-clinical in vivo models of lung cancer

Download en

03/26/2019

Scientific Clinical | Nanobiotix announces its clinical registration plan in Head and Neck cancers for the United States following FDA feedback

Download en

03/15/2019

Financial | Nanobiotix 2018 Annual Results

Download en

03/04/2019

Financial | Nanobiotix receives €14 million through the second tranche disbursement of financing from the European Investment Bank

Download en

02/28/2019

Financial | Nanobiotix 2018 Q4 and annual revenues

Download en

01/16/2019

Financial | Nanobiotix Plans to Conduct Registered Public Offering in the United States

Download en

01/07/2019

Scientific Clinical | Nanobiotix and MD Anderson Cancer Center announce a large-scale, comprehensive clinical collaboration on NBTXR3

Download en

11/15/2018

Financial | Nanobiotix revenues for the 3rd quarter of 2018

Download en

10/19/2018

Scientific Clinical | NANOBIOTIX: Positive phase II/III results for NBTXR3 in Soft Tissue Sarcoma presented at ESMO

Download en

10/16/2018

Financial | Nanobiotix receives first tranche disbursement of 16 million euros financing from European Investment Bank

Download en

09/26/2018

Scientific Clinical | Nanobiotix to present positive results from its phase II/III clinical trial of NBTXR3 in patients with STS and other ongoing phase I/II trials at ESMO and ASTRO

Download en

09/20/2018

Scientific Clinical | Nanobiotix: Update on Head and Neck Phase I/II Trial with NBTXR3 and Other program data presented at ImmunoRad 2018

Download en

09/04/2018

Financial | Nanobiotix half year results for the six months ended June 30, 2018

Download en

07/26/2018

Financial | Nanobiotix signs a 40 M€ non-dilutive financing agreement with the European Investment Bank

Download en

07/12/2018

Financial | NANOBIOTIX revenue for the 2nd quarter of 2018

Download en

06/21/2018

Scientific Clinical | Nanobiotix announces positive phase II/III topline data in soft tissue sarcoma with NBTXR3

Download en

06/06/2018

Financial | NANOBIOTIX’ Management statement on recent share price variation

Download en

05/15/2018

Financial | NANOBIOTIX revenue for the 1st quarter of 2018

Download en

05/03/2018

Scientific Clinical | Nanobiotix partners with Weill Cornell Medicine on pre-clinical studies to evaluate the impact of NBTXR3 on cGAS-STING pathway in mammary cancers

Download en

04/26/2018

Financial | NANOBIOTIX selected to enter Euronext’s Tech 40 Label

Download en

04/17/2018

Scientific Clinical | AACR annual meeting 2018: Nanobiotix presented preclinical data showing NBTXR3 nanoparticles can activate the cGAS-STING pathway

Download en

04/10/2018

Scientific Clinical | The University of Texas MD Anderson Cancer Center and Nanobiotix have an agreement to run immunotherapeutic pre-clinical research in lung cancer combining NBTXR3 & Nivolumab

Download en

03/30/2018

Financial | Nanobiotix 2017 Annual Results

Download en

02/28/2018

Financial | Nanobiotix 2017 Q4 and annual revenues

Download en

01/22/2018

Scientific Clinical | Nanobiotix presents first promising data from Phase I/II Liver Cancers trial of NBTXR3 at American Society Of Clinical Oncology Gastrointestinal Annual Meeting

Download en

01/11/2018

Scientific Clinical | Nanobiotix partners with the Providence Cancer Institute to run immunotherapeutic preclinical research in pancreatic cancers

Download en

08/08/2019

Nanobiotix launches a private placement

Download en

12/26/2017

Corporate | Nanobiotix: 2017 review and 2018 expected milestones

Download en

12/26/2017

Scientific Clinical | FDA approves Nanobiotix’s first Immuno-Oncology trial

Download en

11/15/2017

Financial | Nanobiotix revenues for the 3rd quarter of 2017

Download en

11/13/2017

Scientific Clinical | Nanobiotix presented new clinical and pre-clinical data confirming NBTXR3’s significant potential role in Immuno-Oncology at SITC Annual Meeting

Download en

11/09/2017

Scientific Clinical | Nanobiotix provides update on the global development of its lead product NBTXR3

Download en

10/31/2017

Financial | Nanobiotix successfully completes approximately eur 27.2 million placement of new shares

Download en

10/30/2017

Financial | Nanobiotix launches capital increase by means of an accelerated bookbuild offering

Download en

Nanobiotix launches capital increase by means of an accelerated bookbuild offering

The following pages contain information regarding the placement of Nanobiotix. For regulatory reasons, the distribution of the content of such information is restricted. Consequently, please fill out the fields below to access such information.

Your country:

Access to this information is restricted to persons who are located outside the United States, Canada, Japan and Australia.

This information is not intended for, and shall not be
accessible, published, distributed or circulated to persons resident or located in the United States of America (the “United States”, which shall include its territories and possessions), Canada, Japan or Australia, and is not an offer to subscribe for or sell, nor a solicitation of an offer to subscribe for or buy shares of Nanobiotix in the United States, Canada, Japan or Australia.
With respect to Member States of the European Economic Area that have transposed European Directive 2003/71/EC of the European Parliament and European Council (as amended in particular by Directive 2010/73/EU to the extent that the said Directive has been transposed into each Member State of the European Economic Area) (the “Prospectus Directive”), no action has been taken or will be taken topermit a public offering of the securities of 
 Nanobiotix which would require the publication of a prospectus in any Member State. Shares in Nanobiotix may not be offered or sold in the United States unless registered with the Securities and Exchange Commission under the U.S. Securities Act of 1933, as amended, or unless an exemption from such registration applies. Nanobiotix does not intend to register securities or conduct a public offering in the United States, or in
any other jurisdiction. Access to the information and documents contained in the following pages may be illegal in certain countries and only certain categories of persons may be authorized to access this information and these documents. Any person resident in a country other than France, the United States, Canada, Japan or Australia who wishes to
access the information and documents contained on this website must first satisfy himself that he is not subject to local laws or regulations prohibiting or restricting such right of access or requiring registration or approval of the securities in order to acquire them. Nanobiotix will not accept any liability arising out of the breach by any person of the applicable laws or regulations.
I therefore certify that:
(1) I am not a resident of the United States, Canada, Australia or Japan nor am I currently physically present in any one of those countries;
(2) I am authorized to access the information and documents presented on thiswebsite without being subject to any legal restriction and without any further actionbeing necessary on the part of Nanobiotix.
I have read and understood the above declarations and certify below that they areaccurate, and hereby undertake to comply with all the conditions set forth on thispage.

Sorry

Access to this information is restricted to persons who are located outside the United States, Canada, Japan and Australia.

10/23/2017

Scientific Clinical | Nanobiotix completes patient inclusion for Phase II/III trial of NBTXR3 in soft tissue sarcoma

Download en

09/28/2017

Scientific Clinical | Nanobiotix plans to conduct its first clinical trial with NBTXR3 in combination with immune checkpoint inhibitors in the U.S.

Download en

08/31/2017

Financial | Nanobiotix half year results for the six months ended 30 June 2017

Download en

07/12/2017

Financial | Nanobiotix revenues for the 2nd quarter of 2017

Download en

06/15/2017

Scientific Clinical | NANOBIOTIX: new translational data presented at ASTRO, NCI AND SITC’S Immunotherapy Workshop

Download en

06/05/2017

Scientific Clinical | NANOBIOTIX: promising data from phase I/II Head and Neck cancer trial with NBTXR3 presented at the American Society of Clinical Oncology’s Annual Meeting

Download en

05/18/2017

Scientific Clinical | NANOBIOTIX announces first positive Human data showing that NBTXR3 could become a backbone in Immuno-Oncology

Download en

05/15/2017

Financial | Nanobiotix revenue for the 1st quarter of 2017

Download en

04/28/2017

Financial | Nanobiotix: 2016 Annual Results

Download en

04/07/2017

Financial | Nanobiotix successfully completes approx. EUR 25.1 million private placement of new shares

Download en

04/04/2017

Corporate | Nanobiotix expands its clinical development in Head and Neck cancer and Immuno-Oncology ; new clinical data to be presented at ASCO

Download en

03/23/2017

Scientific Clinical | NANOBIOTIX: the Independent Data Monitoring Committee recommends the continuation of the ongoing phase II/III trial of NBTXR3 in Soft Tissue Sarcoma

Download en

03/07/2017

Scientific Clinical | Nanobiotix to present preclinical data on nanoparticle radioenhancer NBTXR3 at the AACR Annual Meeting 2017

Download en

02/28/2017

Financial | Nanobiotix 2016 Q4 and annual revenues

Download en

02/07/2017

Corporate | Nanobiotix appoints senior executive from pharmaceutical industry, as Chief Operating Officer

Download en

01/31/2017

Corporate | Nanobiotix: 2016 review and 2017 anticipated milestones

Download en

12/14/2016

Scientific Clinical | Nanobiotix reports positive Phase I/II preliminary data on feasibility and safety of NBTXR3 in liver cancers trial

Download en

11/28/2016

Scientific Clinical | Nanobiotix Provides Update on Global Development of Lead Product NBTXR3

Download en

11/15/2016

Financial | Nanobiotix revenue for Q3 2016

Download en

11/14/2016

Scientific Clinical | Nanobiotix presents NBTXR3 preclinical data demonstrating its potential usage as in situ vaccine for cancer

Download en

10/20/2016

Scientific Clinical | Nanobiotix’s partner, PharmaEngine, has launched a new NBTXR3 clinical trial in head and neck cancers in Asia

Download en

10/03/2016

Corporate | Nanobiotix Strengthens U.S. leadership with appointments of Head of U.S. Clinical Development and Director of Investor Relations

Download en

09/19/2016

Financial | Bpifrance grants Nanobiotix a 2M€ interest-free loan to support final development stage of lead product, NBTXR3

Download en

09/13/2016

Corporate | Nanobiotix announces submission for first market approval of lead product NBTXR3 in Europe

Download en

08/31/2016

Financial | Nanobiotix half year results for the six months ended 30 June 2016

Download en

07/13/2016

Financial | Nanobiotix revenue for Q2 2016

Download en

07/06/2016

Scientific Clinical | Nanobiotix reports successful results from Phase I/II Trial of NBTXR3 in Head & Neck Cancer

Download en

06/14/2016

Financial | Nanobiotix announces exercise of warrants by Capital Venture International

Download en

05/31/2016

Corporate | Nanobiotix receives US$1m milestone payment from PharmaEngine

Download en

05/31/2016

Scientific Clinical | Nanobiotix establishes promising preclinical proof-of-concept in Immuno Oncology

Download en

05/13/2016

Financial | Revenue for the 1st quarter of 2016

Download en

04/29/2016

Financial | Nanobiotix 2015 Annual Results

Download en

03/11/2016

Financial | Nanobiotix completes a EUR 21 million private placement

Download en

01/04/2016

Scientific Clinical | FDA approved Investigational New Drug for NBTXR3 in a new clinical study in prostate cancer

Download en

11/13/2015

Financial | Nanobiotix Revenue Q3 2015

Download en

11/13/2015

Scientific Clinical | Nanobiotix’s Soft Tissue Sarcoma pivotal trial progressing well as planned: already 7 countries and 29 sites opened

Download en

08/27/2015

Financial | Nanobiotix Half Year Results for the period ended 30 June 2015

Download en

07/15/2015

Financial | Nanobiotix Revenue Q2 2015

Download en

07/01/2015

Scientific Clinical | Nanobiotix starts Phase I/II clinical trial in liver Metastasis and Hepatocellular Cancer with its lead product NBTXR3

Download en

06/09/2015

Scientific Clinical | Nanobiotix reports positive preliminary results in Head and Neck cancer Phase I/II clinical trial with NBTXR3

Download en

05/13/2015

Financial | Nanobiotix Revenue Q1 2015

Download en

05/11/2015

Scientific Clinical | Nanobiotix expands Soft Tissue Sarcoma pivotal clinical trial across Europe and beyond, according to plan

Download en

04/14/2015

Financial | Nanobiotix 2014 Annual Results

Download en

03/18/2015

Corporate | Nanobiotix appoints its Manufacturing Partner, CordenPharma : another step towards commercialization

Download en

02/27/2015

Financial | Nanobiotix 2014 Q4 and annual revenues

Download en

02/19/2015

Corporate | Professor Robert Langer joins Nanobiotix as Scientific Advisor

Download en

11/25/2014

Financial | Nanobiotix secures financing from a major US investor, to address the US market

Download en

11/14/2014

Financial | Nanobiotix 2014 Q3 Revenues

Download en

10/16/2014

Scientific Clinical | Nanobiotix receives first approval to start phase II/III registration trial in soft tissue sarcoma in Europe

Download en

10/13/2014

Financial | Nanobiotix reaches the second milestone payment of Bpifrance dedicated to NBTXR3 development in liver cancers

Download en

10/08/2014

Scientific Clinical | PharmaEngine will join Nanobiotix’ pivotal trial for NBTXR3 in Soft Tissue Sarcoma to accelerate its development in Asia-Pacific

Download en

09/22/2014

Corporate | Nanobiotix expands operations into the USA

Download en

08/28/2014

Financial | Nanobiotix Half year Results for the period ended 30 june 2014

Download en

07/11/2014

Financial | Nanobiotix 2014 Q2 Revenues

Download en

06/17/2014

Financial | Nanobiotix joins the CAC® PME Index

Download en

06/02/2014

Scientific Clinical | Nanobiotix presents successful Phase I results for its lead nanomedicine product NBTXR3 at ASCO

Download en

05/12/2014

Financial | Nanobiotix Revenue Q1 2014 and new composition shareholding

Download en

04/15/2014

Corporate | Nanobiotix appoints Thierry Otin as Head of Manufacturing and supply

Download en

04/11/2014

Financial | Nanobiotix 2013 Annual Results

Download en

04/01/2014

Scientific Clinical | Nanobiotix selected to present data from NBTXR3 clinical trial at ASCO

Download en

02/10/2014

Scientific Clinical | Nanobiotix sees Clinical Advance in Soft Tissue Sarcoma Pilot Trial with Lead Product, NBTXR3

Download en

01/31/2014

Financial | Nanobiotix 2013 annual revenues

Download en

01/16/2014

Corporate | Nanobiotix strengthens its Supervisory Board

Download en

01/07/2014

Corporate | Nanobiotix 2014 Review, 2015 Anticipated Milestones and Financial Calendar

Download en

12/10/2013

Corporate | Nanomedicine Map reveals the European landscape and potential

Download en

12/06/2013

Scientific Clinical | Nanobiotix strengthens its NanoXray pipeline with the launch of NBTX-TOPO development, the first nanotherapeutic with embedded radar

Download en

11/12/2013

Financial | Nanobiotix Q3 Revenue 2013

Download en

11/07/2013

Corporate | Nanobiotix honored at the INVESTOR AWARDS 2013 in the “Young Talent” category

Download en

09/23/2013

Corporate | Nanobiotix strengthens its management team

Download en

08/30/2013

Financial | Nanobiotix Half Year Results for the period ended 30 June 2013

Download en

07/12/2013

Financial | Nanobiotix 2013 Q2 revenue

Download en

07/03/2013

Corporate | Nanobiotix announces €2.8 million grant from bpifrance to accelerate development of NBTXR3 in a third new indication

Download en

06/26/2013

Scientific Clinical | Nanobiotix announces the selection of its second NanoXray product, NBTX-IV and a collaboration with the NCI for development

Download en

06/13/2013

Scientific Clinical | Nanobiotix receives approval from ANSM to start new Clinical Trial with Lead Product NBTXR3

Download en

06/03/2013

Scientific Clinical | Nanobiotix’s NBTXR3 Achieves Clinical Milestone Reaching Proof-Of- Concept in Phase I Trial of Soft Tissue Sarcoma

Download en

05/15/2013

Financial | Nanobiotix 2013 Q1 revenues

Download en

04/25/2013

Financial | Nanobiotix 2012 Annual Results

Download en

04/03/2013

Corporate | Dr. Laurent Levy, CEO of Nanobiotix, receives the UB Entrepreneurship Award from the University at Buffalo, SUNY

Download en

03/19/2013

Corporate | Nanobiotix Selected to Present at Future Leaders in the Biotech Industry Conference

Download en

02/13/2013

Corporate | Nanobiotix appoints Dr Alain Herrera to the Supervisory Board

Download en

01/25/2013

Financial | Nanobiotix 2012 revenues

Download en

01/14/2013

Financial | 2013 Financial agenda

Download en

01/07/2013

Corporate | Nanobiotix 2013 Review Significant Corporate and Clinical Progress

Download en

12/05/2012

Corporate | Laurent Levy, CEO Nanobiotix, elected Vice-Chairman of the ETPN

Download en

11/13/2012

Scientific Clinical | Phase I Independent Data Monitoring Committee confirms good safety of NBTXR3 in the first group of patients with advanced STS

Download en

10/03/2012

Corporate | Nanomed2020 intends to bring more nanomedicine products to European patients

Download en

08/05/2012

Corporate | PharmaEngine and Nanobiotix Sign Asia-Pacific Exclusive License and Collaboration Agreement for NBTXR3

Download en

05/02/2012

Scientific Clinical | Nanobiotix and Thomas Jefferson University Start Research Collaboration

Download en

04/24/2012

Corporate | Nanobiotix appoints Dr. Bernd Muehlenweg as a member of the Executive Board

Download en

11/24/2011

Financial | Nanobiotix receives 1 million euro from OSEO

Download en

09/13/2011

Scientific Clinical | Nanobiotix Starts Clinical Trial with Lead Product NBTXR3

Download en

04/04/2011

Corporate | Nanobiotix announces changes to the non-executive board

Download en

02/02/2011

Corporate | Nanbiotix welcomes Dr Bernd Mühlenweg as Head of Business Development

Download en

09/07/2010

Corporate | Nanobiotix welcomes Laurent Condomine on board

Download en